Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACIP logoThe Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States...

More

laptop

Register for upcoming February ACIP meeting

February 22-23, 2017

Deadline for registration:
Non-US Citizens: February 1, 2017
US Citizens: February 13, 2017

Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Public Comment Instructions [1 page]

ACIP Recommendations

General Committee-related Information

  • Charter
    Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
  • Members
    Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
  • Articles
    Journal articles about the ACIP.

Guidance

ACIP Flyer

ACIP brochure This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?

ACIP Votes, October 2016

  • ACIP approved the following four recommendations by majority vote on October 19, 2016:
    • Hepatitis B vaccine: birth dose within 24 hours of birth for medically stable infants weighing ≥2000 grams and born to HBsAg-negative mothers; removal of permissive language to delay the hepatitis B birth dose; approve revised statement.
    • Human papillomavirus vaccine: 2-dose schedule for boys and girls initiating HPV vaccination series at 9 to 14 years (0,6-12 months); 3-dose schedule for persons initiating HPV vaccination series at older ages; 3-dose schedule for immunocompromised persons.
    • Meningococcal vaccines: provided guidance on the updated dosing schedules for one serogroup B meningococcal vaccine, MenB-FHbp (Trumenba). For persons at increased risk for meningococcal disease and during serogroup B outbreaks, 3 doses of MenB-FHbp administered at 0, 1-2, and 6 months; when given to healthy adolescents not at increased risk for meningococcal disease, 2 doses of MenB-FHbp at 0 and 6 months.
    • Pertussis-containing vaccines: approve the updated statement, “Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the ACIP.”
  • The 2017 Child/Adolescent and Adult Immunization schedules were approved by majority vote on October 20, 2016.
  • If approved by the CDC Director, the recommendations will become official once published in MMWR.

ACIP Meetings

Top